Starling Oncology, Inc. STLN
$6.94
$0.314.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -292.82% | 66.81% | 54.51% | 2.97% | 13.15% |
| Total Depreciation and Amortization | 13.74% | -0.98% | -5.28% | -4.54% | 1.18% |
| Total Amortization of Deferred Charges | 3.72% | 0.50% | 2.82% | 3.81% | -76.84% |
| Total Other Non-Cash Items | 224.64% | -1,485.66% | -96.49% | -0.10% | 48.81% |
| Change in Net Operating Assets | 1,440.95% | -87.87% | 224.00% | -87.88% | -204.99% |
| Cash from Operations | 639.05% | -168.51% | 125.60% | -23.80% | -104.53% |
| Capital Expenditure | 12.86% | 1.70% | -75.50% | 50.00% | -268.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 12.86% | 1.70% | -75.50% | 50.00% | -498.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -14.50% | 12.94% | -27.16% | -1.25% | 98.81% |
| Issuance of Common Stock | -62.66% | -94.11% | -62.25% | 392.19% | -85.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -678.57% | -100.75% | -64.77% | 439.99% | 141.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 429.19% | -155.61% | 324.26% | 72.12% | 4.86% |